Rxsight Inc Cash Flow Conversion Efficiency
Rxsight Inc cash flow conversion efficiency. Based on the latest financial reports, Rxsight Inc (RXST) has a cash flow conversion efficiency ratio of -0.036x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.54 Million) by net assets ($263.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rxsight Inc (2019–2025)
Cash flow conversion efficiency of Rxsight Inc from 2019 to 2025. This chart illustrates how Rxsight Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Rxsight Inc (RXST) stock price for real-time trading data and today's change.
Rxsight Inc Cash Flow Conversion Ratio Explained
Rxsight Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rxsight Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rxsight Inc ranked by their cash flow conversion efficiency. Also see Rxsight Inc (RXST) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medical Facilities Corporation
TO:DR
|
0.039x |
|
Ndr Auto Components Limited
NSE:NDRAUTO
|
0.023x |
|
Jiangsu Zhongshe Group Co Ltd
SHE:002883
|
0.010x |
|
HARIM Co. Ltd
KQ:136480
|
0.021x |
|
Josef Manner & Comp. AG
VI:MAN
|
-0.119x |
|
Micro Systemation AB (publ)
ST:MSAB-B
|
0.161x |
|
Optimum Communications, Inc.
NYSE:OPTU
|
-0.041x |
|
Comstock Holding Companies Inc
NASDAQ:CHCI
|
0.174x |
Annual Cash Flow Conversion Efficiency for Rxsight Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Rxsight Inc from 2019 to 2025. Review free cash flow generation of Rxsight Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $275.68 Million | $-15.51 Million | -0.056x | +6.62% |
| 2024-12-31 | $281.24 Million | $-16.95 Million | -0.060x | +76.77% |
| 2023-12-31 | $160.36 Million | $-41.59 Million | -0.259x | +60.38% |
| 2022-12-31 | $89.90 Million | $-58.85 Million | -0.655x | -102.41% |
| 2021-12-31 | $138.24 Million | $-44.71 Million | -0.323x | -373.33% |
| 2020-12-31 | $-297.53 Million | $-35.20 Million | 0.118x | -11.27% |
| 2019-12-31 | $-304.61 Million | $-40.62 Million | 0.133x | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more